SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02086071

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Feasibility of New Biological and Histological Samples at Progression for Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)

Feasibility of new biological and histological samples at progression in patients with advanced or metastatic Non Small Cell Lung Cancer (NSCLC). A recent paper from Pr Sequist and coll. has depicted the resistance mechanisms as Thréonine790Methionine (T890M) mutation oncogene cMet (CMet) amplification. Re-biopsies showed in 14% of cases the transition between NSCLC to Small Cells Lung Cancer (SCLC). In 3 patients, resistance mechanisms have disappeared and they became again sensitive to Tyrosine Kinase Inhibitors (TKIs). It is mandatory to have a better description to natural history of the disease. This study will be conducted by the Groupe Français de Pneumo Cancérologie (GFPC) up to 100 patients during 18 Months. Each center will have to define if re-biopsies are possible or not and explain why not.

NCT02086071 Lung Cancer
MeSH: Lung Neoplasms
HPO: Neoplasm of the lung

1 Interventions

Name: re biopsy

Description: re biopsy depending on the location of the pathology

Type: Procedure

Re biopsies faisibility


Primary Outcomes

Description: Feasibility of re-biopsies in patients with advanced or metastatic NSCLC after progression of disease under treatment. If the re-biopsy could not be performed : reason of no re-biopsy. If the biopsy could be performed : site and method of rebiopsy.

Measure: Feasibility of re-biopsies

Time: 18 months / 100 patients

Secondary Outcomes

Description: Comparison of types and numbers of resistances before treatment (on the first biopsy) and after treatement (on the re-biopsy). Appearance and/or disappearance of some resistances.

Measure: Type of resistance

Time: 18 months/100 patients

Description: Description of population: age, performans status, smoking status, sex (number, medium, maximum, minimum). Description of treatment: chemotherapy (type and products), radiotherapy (site), surgery (site)

Measure: Disease management

Time: 18 months / 100 patients

Description: Description and comparison of histology on the first biopsy and on the rebiopsy

Measure: Biological history of the disease

Time: 18 months / 100 patients

Purpose: Basic Science

Single Group Assignment


There are 2 SNPs

SNPs


1 T790M

One of the major resistance mechanisms is the onset of T790M mutation, which induces a non sensitivity to TKIs. --- T790M ---

has depicted the resistance mechanisms as mutation T790M or oncogene cMet (CMet) amplification. --- T790M ---


2 T890M

has depicted the resistance mechanisms as Thréonine790Methionine (T890M) mutation oncogene cMet (CMet) amplification. --- T890M ---



HPO Nodes


HPO:
Neoplasm of the lung
Genes 43
WT1 KRAS SLC22A18 STK11 IRF1 AKT1 C11ORF95 PRKN PPP2R1B ERBB2 TRPV3 TSC1 POU6F2 TSC2 EWSR1 RELA KEAP1 REST DIS3L2 SFTPA2 GPC3 MBTPS2 LMNA PTEN BRAF BRCA2 EGFR RB1 TRIP13 PDGFRB TERT SFTPC PIK3CA TRIM28 DICER1 MAP3K8 HPGD SLCO2A1 H19 TP53 NOTCH3 BAP1 WRN